Kenakin, 2002 - Google Patents
Drug efficacy at G protein–coupled receptorsKenakin, 2002
View PDF- Document ID
- 971509883877280457
- Author
- Kenakin T
- Publication year
- Publication venue
- Annual review of pharmacology and toxicology
External Links
Snippet
Efficacy has been defined in receptor pharmacology as a proportionality factor denoting the amount of physiological response a given ligand imparts to a biological system for a given amount of receptor occupancy. While first defined in terms of response, the concept can be …
- 102000003688 G-protein coupled receptors 0 title abstract description 66
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/566—Immunoassay; Biospecific binding assay using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kenakin | Drug efficacy at G protein–coupled receptors | |
Kenakin | Biased receptor signaling in drug discovery | |
Ballante et al. | Structure-based virtual screening for ligands of G protein–coupled receptors: what can molecular docking do for you? | |
Jacoby et al. | The 7 TM G‐protein‐coupled receptor target family | |
Surgand et al. | A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors | |
Scheer et al. | Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the α1b-adrenergic receptor: effects on receptor isomerization and activation | |
Fanelli et al. | Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis | |
Oliveira et al. | The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure | |
Katada et al. | Structural basis for a broad but selective ligand spectrum of a mouse olfactory receptor: mapping the odorant-binding site | |
Flower | Modelling G-protein-coupled receptors for drug design | |
Vauquelin et al. | G protein‐coupled receptors: a count of 1001 conformations | |
Galandrin et al. | The evasive nature of drug efficacy: implications for drug discovery | |
Luttrell | Minireview: More than just a hammer: ligand “bias” and pharmaceutical discovery | |
Gether | Uncovering molecular mechanisms involved in activation of G protein-coupled receptors | |
Gudermann et al. | Functional and structural complexity of signal transduction via G-protein-coupled receptors | |
Scheer et al. | Minireview: constitutively active G protein-coupled receptors: potential mechanisms of receptor activation | |
McAllister et al. | A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition | |
US20020061599A1 (en) | Method of identifying ligands of biological target molecules | |
Yoshikawa et al. | Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands | |
López-Rodrı́guez et al. | Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine1a receptor ligands to explore the three-dimensional structure of the receptor | |
Nicoli et al. | Classification model for the second extracellular loop of class A GPCRs | |
Umanah et al. | Changes in conformation at the cytoplasmic ends of the fifth and sixth transmembrane helices of a yeast G protein-coupled receptor in response to ligand binding | |
Cawston et al. | Molecular basis for binding and subtype selectivity of 1, 4-benzodiazepine antagonist ligands of the cholecystokinin receptor | |
Huang et al. | Dynamics and mechanistic underpinnings to pharmacology of class A GPCRs: an NMR perspective | |
Yuzlenko et al. | Molecular modeling of A1 and A2A adenosine receptors: Comparison of rhodopsin‐and β2‐adrenergic‐based homology models through the docking studies |